Clinical trials: Dapagliflozin
Nephropathy, Hypoxia
Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes
Background: Inhibiting the sodium-glucose cotransporter-2 (SGLT2) has been observed to reduce risk of cardiovascular events and kidney failure in type 2 diabetes.
- Conditions
- Nephropathy, Hypoxia, Mitochondrial Alteration, Type 1 Diabetes
- Trial name
- Astronaut (NCT04193566)
- Testing
- Forxiga
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Steno Diabetes Center Copenhagen
Healthy Subjects
Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions
The primary objective of this study is to evaluate the bioequivalence between: Dapagliflozin 10 mg tablets from Jiangsu Hansoh Pharmaceutical Group Co., Ltd.,China; and Farxiga® 10 mg tablets from AstraZeneca Pharmaceuticals LP…
- Trial name
- NCT04881006
- Testing
- Dapagliflozin 10 mg tablets, Farxiga® 10 mg tablets
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Takotsubo Cardiomyopathy
Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy
The goal of this research study is to further understand the physiological mechanisms involved in a heart condition called takotsubo cardiomyopathy, also known as broken heart syndrome.
- Trial name
- TAKO MEMRI (NCT07491718)
- Testing
- Bisoprolol, Valsartan, sacubitril/ valsartan
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Type2 Diabetes
Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults
A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin 5 mg and Empagliflozin 25 mg or Dapagliflozin 10 mg after Oral Administration in…
- Trial name
- NCT03766724
- Testing
- Evogliptin→Evogliptin+Empagliflozin→Empagliflozin, Empagliflozin→Evogliptin→Evogliptin+Empagliflozin, Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Obesity
Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity
Obesity has increased to alarming levels in the world. Currently it is estimated that it occurs in a third of the world's population and it is expected that by 2030, 20% of the world's adult population will suffer from obesity…
- Trial name
- NCT03710460
- Testing
- Dapagliflozin, Dapagliflozin plus Metformin XR, Metformin XR
- Where
- Mexico
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Guadalajara
Type 2 Diabetes Mellitus
Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects
The purpose of this study is determine that Dapagliflozin has no effect on the pharmacokinetics (PK) or pharmacodynamics (PD) of warfarin when dapagliflozin is coadministered with warfarin.
- Trial name
- NCT00904176
- Testing
- Dapagliflozin, Warfarin, Digoxin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Dapagliflozin (Forxiga), Atrial Fibrillation (AF)
Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation
Investigator study the efficacy and safety outcomes of Dapagliflozin use among newly diagnosed Atrial fibrillation patients when underwent rhythm control strategy regardless their diabetic status.
- Trial name
- NCT06759909
- Testing
- Dapagliflozin (DAPA)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Healthy, Fasting
The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers
This is a single dose, randomized, open-label, two-way crossover study to investigate the food-effect bioavailability of the fixed-dose combination of Gemigliptin/Dapagliflozin/Metformin 50/10/1000 mg in healthy volunteers under…
- Conditions
- Healthy, Fasting, Fed
- Trial name
- NCT07396844
- Testing
- Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg
- Where
- Thailand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- LG Chem
Aging
SGLT2 Inhibition in Older Obese Adults With Pre-diabetes
Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose concentration secondary to increased glucose…
- Trial name
- SGLT2i (NCT04401904)
- Testing
- Dapagliflozin 10 mg, Nutritional counseling
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
STEMI - ST Elevation Myocardial Infarction, Left Ventricular Systolic Dysfunction
The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction
300 STIMI patients with LV systolic dysfunction will be divided into two equal groups (Group I (Study arm, n=150); will receive dapagliflozin plus conventional therapy and group (II) Control arm (n=150); will receive conventional…
- Trial name
- NCT05045274
- Testing
- Dapagliflozin 10Mg Tab
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Assiut University
Healthy
A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers
The purpose of this study is to compare the pharmacodynamics (ie, how the drug affects the body) of canagliflozin with the pharmacodynamics of dapagliflozin.
- Trial name
- NCT01877889
- Testing
- Canagliflozin, Dapagliflozin
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag International NV
Chronic Kidney Diseases
Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients
Chronic kidney disease (CKD) is a common disease affecting 10-12% of the adult population and characterize with high-risk cardiovascular morbidity and mortality with progression of CKD.
- Trial name
- DAPA-GUT (NCT05965440)
- Testing
- impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Type 2 Diabetes
The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes
The study is a randomised double blind placebo control cross over trial with 4 weeks washout period. The expected duration of participant participation is 103 days.
- Trial name
- SINGLED (NCT04219124)
- Testing
- IMP oral tablet
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Healthy Volunteer
A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants
This study is intended to evaluate the PK, safety, and tolerability of balcinrenone/dapagliflozin given as a single dose capsule to healthy Chinese participants.
- Trial name
- NCT06651021
- Testing
- balcinrenone/dapagliflozin
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Lupus Nephritis
Assessment of Safety and Efficacy of SGLT2is Among LN Patients
The aim of this study is to assess the safety and efficacy of SGLT2is among LN patients.
- Trial name
- NCT06113900
- Testing
- Dapagliflozin 10mg Tab orally once daily
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Bioequivalence, Fixed Dose Combination Tablets
A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects
This is a bioequivalence study to compare 2 fixed-dose combination tablets of dapagliflozin/metformin XR manufactured at 2 different plants in healthy subjects under fasting and fed conditions
- Conditions
- Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
- Trial name
- NCT02637037
- Testing
- dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
STEMI
Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients
Methodology This study will enroll (120) patients presenting with acute anterior STEMI who will undergo early reperfusion presenting at Helwan University Hospitals and Ain Shams University Hospitals.
- Trial name
- NCT05957887
- Testing
- Dapagliflozin
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Mohamed Nabil Elkholy
Diabetes Mellitus, Type 2
Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects
The purpose of the study is to determine the effect of glimepiride on dapagliflozin and the effect of dapagliflozin on glimepiride in healthy volunteers.
- Trial name
- NCT00562250
- Testing
- Dapagliflozin, Glimepiride, Dapagliflozin + Glimepiride
- Where
- Argentina
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects
The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single oral doses of 0.001 mg to 2.5 mg dapagliflozin in healthy subjects.
- Trial name
- ULDS (NCT01135446)
- Testing
- dapagliflozin
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
T2DM (Type 2 Diabetes Mellitus)
The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2
To evaluate a pharmacokinetic drug interaction between AJU-A51R1 and AJU-A51R2 in healthy male volunteers.
- Trial name
- NCT04970940
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.